P3 study is a futility study, which scares me a bit, but the subset of patients looks promising and the endpoints are realistic. This one is the real deal. If it breaks 5 bucks, its again off to the races!
I'm not selling, either, although I agree that some of the recent run-up has already been built into the expected jump today. Bottom line: $7.50 share price before next Q earnings, and 10 bucks by EOY.